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Histidine residueyt b561), a transmembrane protein that shuttles reducing equivalents derived
from ascorbate, has two heme centers with distinct spectroscopic signals and reactivity towards ascorbate.
The His54/His122 and His88/His161 pairs furnish axial ligands for the hemes, but additional amino acid
residues contributing to the heme centers have not been identiﬁed. A computational model of human cyt b561
(Bashtovyy, D., Berczi, A., Asard, H., and Pali, T. (2003) Protoplasma 221, 31–40) predicts that His92 is near the
His88/His161 heme and that His110 abuts the His54/His122 heme. We tested these predictions by analyzing
the effects of mutations at His92 or His110 on the spectroscopic and functional properties. Wild type
cytochrome and mutants with substitutions in other histidine residues or in Asn78 were used for
comparison. The largest lineshape changes in the optical absorbance spectrum of the high-potential (bH)
peak were seen with mutation of His92; the largest changes in the low-potential (bL) peak lineshape were
observed with mutation of His110. In the EPR spectra, mutation of His92 shifted the position of the g=3.1
signal (bH) but not the g=3.7 signal (bL). In reductive titrations with ascorbate, mutations in His92 produced
the largest increase in the midpoint for the bH transition; mutations in His110 produced the largest decreases
in ΔA561 for the bL transition. These results indicate that His92 can be considered part of the bH heme center,
and His110 part of the bL heme center, in adrenal cyt b561.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionAdrenal cytochrome (cyt1) b561wasﬁrst observed in bovine adrenal
medullae [1] and later found in several other tissues [2–6]. Cyt b561
spans the chromafﬁn granule (CG) membrane in adrenal medullae
[7,8] and the cytochrome is believed to reducemonodehydroascorbate
in the CG lumen (matrix) at the expense of cytoplasmic ascorbate [9],
thus providing reducing equivalents for lumenal monooxygenases
such as dopamine β-hydroxylase [10]. Genetic analyses have revealed
that the adrenal cyt b561 is the prototype of a large protein family
distributed widely in vertebrate, invertebrate and plant tissues [11].
Native cyt b561 has twomolecules of heme per polypeptide [12,13],
and two major forms of ferric heme are apparent in the EPR spectraCG, chromafﬁn granules; CD,
ce; HALS, highly axial low-spin
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ll rights reserved.of cyt b561 in intact CG membranes and in the puriﬁed, detergent
solubilized cytochrome [12–16]. One is a conventional low-spin spe-
cies with a signal at g=3.1 that has a redox potential of ~160 mV (the
“high-potential” or bHheme center), the other is a highly axial low-spin
(HALS) species with a signal at g=3.7 that has a redox potential of
~60 mV (the “low-potential” or bL heme center) [14,17,18]. Spectro-
scopic and mutagenic studies [12–16,19–21] have supported earlier
models [19,22,23] for adrenal cyt b561 in which each heme has two
histidines as axial ligands, with the His54/His122 pair (residue num-
bering follows the systemof Okuyama et al. [22]) furnishing ligands for
one heme and the His88/His161 pair furnishing ligands for the other
heme. These four histidines in the bovine adrenal cytochrome are
completely conserved among cyt b561 family members [11,24]. Our
recent mutagenic study of histidines 54, 88, 122 and 161 in bovine cyt
b561 [15] is consistent with their roles as axial ligand to cyt b561 hemes.
Besides the axial ligands to heme, bovine adrenal cyt b561 has three
other histidine residues, at positions 92, 109, and 110. His109 is not
conserved in the four vertebrate subfamily groups corresponding to
the four major cyt b561 isoforms identiﬁed so far in humans (Fig. 1).
Both His92 and His110 are fully conserved in the subset of vertebrate
subfamily A members that we term group A2; this group includes
adrenal cyt b561. Group A1.1members, which include human duodenal
Fig. 1. Sequence alignment for four human cyt b561 family members with analogous
sequences from other vertebrate species. The classiﬁcation scheme of Tsubaki et al. [11]
recognized twelve cyt b561 subfamilies among eukaryotes. Sequence analysis by ClustalX
[59] of currently known human cyt b561 familymembers indicates that three of the human
proteins (termed A1.1, A1.2 and A2) are in subfamily A and one (E1) is in subfamily E
described by Tsubaki et al. [11]; we have subdivided the original subfamilies A and E to
reﬂect the divergent sequence patterns among their members. The shaded boxes and
arrows indicate the residues corresponding to His92 and His110 in bovine adrenal cyt b561
(Btaur A2). Subfamily A1.1 includes duodenal cyt b561, subfamily E1 includes the putative
tumor suppressor protein (101F6). Hsap, Homo sapiens; Btaur, Bos taurus; Cfam, Canis
familiaris; Drer, Danio rerio; Ggal, Gallus gallus; Mdom, Monodelphia domesticus; Mmul,
Macaca mulatta; Mmusc, Mus musculus; Oari, Ovis aries; Ptrog, Pan troglodytes; Ppyg,
Pongo Pygmaeus; Rnorv, Rattus norvegicus; Sscro, Sus scrofa; Tnig, Tetraodon nigriviridis.
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gine at position 92. In group A1.2 members, His110 is again fully
conserved but His92 is not. In group E1, which includes the putative
human tumor suppressor protein (101F6) [26], position 92 is fully
conserved as a glutamine andposition 110 is fully conserved as a lysine.
This pattern of generally strong conservation, whether as histidine or
as another amino acid, within the subgroups at positions 92 and 110suggests that the sidechain structures at these positions have some
specialized functional importance.
Crystallographic information is not available for cyt b561 but a
computational model has been developed for the four transmembrane
helices carrying the axial ligands for the two hemes [23]. This model
was based on conservation, among the 26 members of the b561 family
known at the time, of four histidine residues presumed to be ligands to
the two hemes and of six predicted transmembrane segments. The
modeling of the central four helices was constrained by the require-
ment for ligation of the hemes by the conserved histidines and for
outward orientation of the helix faces predicted to be lipid-exposed.
One remarkable prediction of this structural model is that three, and
not two, histidine residues ﬂank each heme (Fig. 2). Thus, His110 is
predicted to be close to His54 near the face of one heme and His92
close to His88 near the face of the second heme. Such an arrangement
suggests that His92 and/or His110 might be additional components of
the heme centers in cyt b561. To evaluate this possibility, we have
constructed cDNAs encoding substitutions of His92 or His110 in the
bovine cytochrome. The corresponding mutant proteins, along with
mutants in the ﬁve other histidines for comparison, were expressed in
a newly developed bacterial system [27]. The recombinant proteins
were examined to evaluate the effects of the mutations on expression
levels, spectroscopic characteristics and functional interactionwith the
physiological reductant, ascorbate. The results indicate that His92 and
His110 can indeed be considered components of the heme centers,
namely the bH heme for His92 and the bL heme for His110. These
data provide independent evidence for a revised topology of hemes in
cyt b561 [15] in which the high-potential heme on the cytoplasmic
surface of the chromafﬁn membrane serves as a donor of electrons for
the low-potential heme on the lumenal side.
2. Materials and methods
2.1. Materials
Hemin, sodium ascorbate, δ-aminolevulinic acid, isopropyl-1-thio-β-D-galactopyr-
anoside, guanidine, ampicillin, chloramphenicol, Sephacryl 300 HR beads, bovine
pancreatic trypsin, soybean trypsin inhibitor type I-S, egg lysozyme and the redox dyes
were from Sigma (St. Louis, MO). n-Dodecyl-β-D-maltoside was from Anatrace
(Maumee, OH). Restriction enzymes and other DNAmodifying enzymeswere purchased
from New England BioLabs (Beverly, MA). Oligonucleotides were obtained from
Integrated DNA Technologies (Coralville, IA). Reagents for DNA extraction and
puriﬁcation were from Qiagen (Valencia, CA). Immunoblotting reagents were from
Bio-Rad (Hercules, CA). Plasmid vector pET43.1a, Benzonase nuclease, rLysozyme
Solution, and Protease Inhibitor Cocktail Set III (without EDTA) were purchased from
Novagen (Madison, WI). Escherichia coli strains DH5α and BL21Star(DE3), and anti-His
(C-term) monoclonal antibody were from Invitrogen (Carlsbad, CA). The chaperone
plasmid pT-groE was generously provided by Dr. Lee-Ho Wang (University of Texas
Health Science Center at Houston). TALON metal afﬁnity resin was purchased from BD
Biosciences Clontech (Palo Alto, CA). DNA sequencing was performed at Microbiology
and Molecular Genetics Core Facility, University of Texas Health Science Center at
Houston (Houston, TX).
2.2. Constructs for recombinant, His-tagged wild type and mutant cyt b561
Construction of a pET43.1a plasmid containing sequence coding for bovine adrenal
cyt b561, designated pET43.1a-b561C6H, is described elsewhere [27]. Point mutations
were introduced using the QuikChange Site-directed Mutagenesis kit (Stratagene, La
Jolla, CA) and the pET43.1a-b561C6H expression plasmid as the template. The mutagenic
primers, together with their complementary (antisense) strands, were used in a
PfuTurbo polymerase-initiated reaction. The original, methylated DNA strand was
digested with DpnI, and the remaining DNA was transformed into E. coli XL-10
competent cells. The mutated clones were veriﬁed by DNA sequencing.
2.3. Expression and puriﬁcation of His-tagged wild type and mutant cyt b561
Procedural details are described elsewhere [27]. Brieﬂy, the BL21Star(DE3)/pT-groE
E. coli strain was transformed with the desired expression plasmid and grown in the
presence of heme, δ-aminolevulinic acid, and isopropyl-1-thio-β-D-galactopyranoside
for 24 h at 20 °C. The recombinant cytochrome was solubilized from the membrane
fraction by stirring overnight at 0–4 °C in 0.1 M potassium phosphate (pH 7.2)
containing 5% glycerol and ~1.5 g DM/g total protein. Unextractedmaterial was pelleted
by centrifugation and the pH of the crude detergent extract was adjusted to 7.3–7.5.
Fig. 2. Computational model of helices 2–5 of human cyt b561 [23] showing the residues targeted for mutagenesis. Y109 in human cyt b561 is a histidine in the bovine cytochrome. The
heme center coordinated by His 54 and His122 is oriented toward the lumenal side of the CG membrane, and the heme coordinated by His 88 and His161 is oriented toward the
cytoplasmic side [39,40].
Table 1
Expression of wild type and mutant cyt b561 in the bacterial system
Construct Total recombinant
cyt b561 proteina
(nmol/L culture)
Extractable recombinant
cyt b561 proteinb
(nmol/L culture)
Functional
cyt b561c
(nmol/L culture)
Wild type 162 (100) 169 (100) 134 (100)
N78K 254 (157) 247 (146) 227 (169)
H54Q 1.4 (0.9) NDd NDd
H88Q 41 (25) 9.3 (5.5) NDd
H92Q 78 (48) 69 (41) 52 (39)
H109Y 128 (79) 116 (69) 117 (87)
H110Q 120 (74) 115 (68) 152 (113)
H122Q 1.7 (1.0) NDd NDd
H161Q 40 (25) 13 (7.7) NDd
a Immunoreactive protein in cell lysate determined by dot blot assay; the percentage
of the wild type value is given in parentheses.
b Immunoreactive protein in detergent extract determined by dot blot assay; the
percentage of the wild type value is given in parentheses.
c Ascorbate-reducible cytochrome in detergent extract calculated from A561(red)–
A575(ox) and the difference extinction coefﬁcients determined for the individual
puriﬁed proteins; the percentage of the wild type value is given in parentheses.
d Not detected.
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Biosciences Clontech) and Sephacryl 300 HR [27]. The procedure resulted in ~90%
electrophoretically pure recombinant cytochrome except for mutants at residues 54, 88,
122, and 161. To control for potential contributions of endogenous bacterial proteins in
these less-puriﬁed mutants, detergent extracts of membranes from control bacteria
were subjected to the same chromatographic steps and brought to a similar protein
concentration as the recombinant cyt b561 samples for spectroscopic evaluation.
2.4. Assay of protein, cyt b561, and heme content
Total protein was assayed with a modiﬁed Lowry method using bovine serum
albumin as the standard [28]. Recombinant wild type cyt b561 content was calculated
using the reduced (dithionite-treated) minus oxidized (ferricyanide-treated) difference
absorption coefﬁcients (561–575 nm) determined for the individual puriﬁed wild type
and mutant proteins. Dot blot assay [29] of recombinant cyt b561 used antibody against
the His tag, with puriﬁed wild type protein as the standard. Heme content was
determined by the pyridine hemochrome method [30], using a difference absorption
coefﬁcient (556–538 nm) of 24.5 mM−1 cm−1 [31].
2.5. Electrophoretic and immunoblot analyses
The general procedures have been described [13,27]. Levels of recombinant cyt b561
mutant protein in partially puriﬁed samples were determined by dot blot assay [29]
using a monoclonal antibody against a C-terminal His tag (Invitrogen) and a standard
solution of homogeneous N78K mutant. The densitometry value for each dot was
corrected for the adjacent background. The dot blot assay typically has a useful range of
0.5–200 ng of target protein.
2.6. Electronic absorption spectroscopy
Recombinant cytochrome samples puriﬁed by metal ion chromatography (in most
cases followed by gel ﬁltration chromatography) were oxidized by incubation with
0.1 mM potassium ferricyanide and then chromatographed on a 10-DG desalting
column (BioRad) in 0.1 M potassium phosphate, pH 7.2, containing 0.075% DM and 20%
glycerol. Absorbance spectra were recorded at room temperature in 0.1 M potassium
phosphate, pH 7.2, containing 0.075% DM and 10% glycerol in 1-cm pathlength quartz
cuvettes in a Shimadzu Model 2101PC spectrophotometer. Spectra were scanned at
20 nm/min, with 20 data points/nm and a spectral band width of 0.5 nm. The
approximation of the difference spectra of high- and low-potential heme centers by
three Gaussian components was done with Origin 6.1 (OriginLab, Northampton, MA).
2.7. Ascorbate titrations of cyt b561 and mutants
For ascorbate titrations, the pre-oxidized cytochrome b561 sample (~4 μM) in
100 mM potassium phosphate buffer (pH 7.2) containing 0.075% (w/v) n-dodecyl-β-D-
maltoside was placed in a 1-cm pathlength quartz cuvette and titrated with ascorbate.
The standard titration uses 17 levels of ascorbate: 0, 0.13, 0.40, 0.80, 2.13, 4.78, 8.70, 21.9,
48.3, 87.7, 219, 481, 875, 2180, 4780, 9960, and 20,200 µM. The system was allowed to
equilibrate completely after each addition of ascorbate before the spectrum was
recorded; ~5 min was found to be sufﬁcient. All ascorbate stock solutions were freshly
made, the pH adjusted to 7.2, and kept on ice and protected from light. The extent of
reduction was calculated from the increase in A561, corrected for dilution. Some ascor-
bate titrations were performed under anaerobic conditions in a sealed titrator [32].2.8. Potentiometric titrations
The procedure for potentiometric titrations of the ferric/ferrous heme couples in
recombinant cyt b561 has been described previously [27]. Data for the fraction of
maximal change in A561 (F) as a function of the redox potential (E) was ﬁtted to the
equation: F=(1−FH)/ (1+10^((E−Em(bL)) /59))+FH/(1+10^((E−Em(bH)) /59)), where FH
and (1−FH) are the fractions of the maximal absorbance change associated with the
high- and low-potential hemes, respectively, Em(bL) and Em(bH) are the midpoint
potentials for the low- and high-potential hemes, respectively.
2.9. EPR spectroscopy
Each sample was concentrated by ultraﬁltration, oxidized with ferricyanide and the
buffer was exchanged to 0.1 M potassium phosphate, pH 7.2, containing 18% glycerol
and 0.08% DM by chromatography on a 10-DG column before transfer to a quartz EPR
tube and freezing in a dry ice/acetone bath. The samples were stored in liquid nitrogen
until the EPR spectra were recorded with a Bruker EMX EPR spectrometer. The liquid
helium system included an Oxford GFS 600 transfer line, an ITC 503 temperature
controller, and an ESR 900 cryostat.
3. Results
3.1. Expression efﬁciency of wild type and mutant cyt b561
Expression vectors were constructed for wild type cyt b561 and for
mutants with substitutions at His92 and His110. For comparison,
Table 2
Optical spectral parameters and heme stoichiometry of oxidized (ox) and dithionite-reduced (red) states of wild type and mutant cyt b561
WT N78K H88Q H88Y H92Q H92Y H109Y H110Q H110Y H161Q H161Y
ASoret/hemea (ox) 122 (415) 113 (415) 110 (411) 120 (408) 120 (416) 110 (416) 127 (415) 115 (415) 110 (415) 110 (411) 130 (414)
ASoret/hemea (red) 187 (427) 174 (427) 120 (427) 130 (425) 196 (428) 183 (428) 197 (427) 171 (427) 159 (427) 130 (427) 110 (427)
Abeta/hemea (red) 14 (530) 14 (530) 14 (530) 14 (536) 15 (530) 14 (530) 16 (529) 14 (529) 14 (530) 14 (531) 16 (530)
Aalpha/hemea(red) 30 (561) 30 (561) 16 (561) 16 (561) 31 (562) 31 (561) 33 (560) 29 (561) 26 (561) 17 (560) 17 (560)
ASoret/A280 (ox) 3.2 3.3 ndb nd 2.9 3.0 3.1 3.3 2.8 nd nd
ASoret/A280 (red) 4.9 5.2 nd nd 4.7 4.8 4.7 4.9 4.4 nd nd
A561(red)–A575 (ox)c 54.4 48.9 nd nd 48.1 54.1 53.3 49.7 40.5 nd nd
Heme/monomerd 1.94 1.91 1.3 0.9 1.78 1.98 1.87 1.98 1.85 1.3 1.6
Values represent averages from at least two measurements. Puriﬁed protein was used except for the His88 and His161 mutants.
a Extinction coefﬁcient ((mM heme)−1 cm−1); heme determined by pyridine hemochrome assay; peak position (nm) in parentheses.
b Not determined.
c Difference extinction coefﬁcient ((mM monomer)−1 cm−1).
d Heme determined by pyridine hemochrome; recombinant protein determined by assay of total protein and densitometry of electrophoretic gels except for His88 and His161
mutants, where recombinant protein was determined by immunoblot.
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the bovine cytochrome (residues 54, 88, 109, 122, and 161). As a
control, an Asn→Lys substitution was made at residue 78, which is
oriented away from both hemes in the 3D model (Fig. 2). Glutamine
and tyrosine substitutions were made for His92 and His110, and a
tyrosine substitution was made for His109. Four substitutions were
designed for the histidines identiﬁed as axial ligands (residues 54, 88,
122 and 161): Gln, Leu, Tyr and Met.Fig. 3. Absorbance spectra of wild type andmutant cyt b561. Oxidized (thick line), ascorbate (1
wild type (A; 2.4 µM heme), H92Q (B; 2.5 µM heme), and H161Q (C; 8.9 µM heme, 1.55
membranes processed through the same puriﬁcation procedures as the other samples, withThe initial results indicated that the level of expression in the
bacterial system was not sensitive to which amino acid replaced
histidine (data not shown), and the glutamine mutants were chosen
for a quantitative comparison of expression efﬁciency. The molecular
mass of each recombinant cyt b561 protein was examined by
immunoblot and the level of recombinant protein in whole cell
lysates and in detergent extracts was quantiﬁed by a dot blot assay.
The amount of ascorbate-reducible b-type cytochrome in the7–21 mM)-treated (dotted line), and dithionite-treated (thin line) spectra are shown for
mg total protein/mL). The control spectra (D) are from a detergent extract of control
a total protein concentration of 1.64 mg/mL.
Fig. 4. EPR spectra of low-spin heme signals from puriﬁed wild type andmutant cyt b561.
Panel A: homogeneous samples of wild type (WT, 143 µM heme), N78K (163 µM heme),
H92Q (118 µM heme), H92Y (132 µM heme), H109Y (112 µM heme), H110Q (155 µM
heme) and H110Y (106 µM heme). The signal amplitudes are normalized to the heme
concentration and the g values are indicated. Panel B: partially puriﬁed samples of
H88Q (69 µMheme, 8.7mg total protein/mL), H161Q (61 µM heme, 9.3 mg total protein/
mL), and a detergent extract from control membranes subjected to the same
puriﬁcation protocol (8.2 mg total protein/mL). The spectrometer conditions were:
frequency, 9.60 GHz; modulation amplitude, 10.9 G; power, 4.0 mW; and temperature,
4 K.
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protein.
An immunoreactive band with the same electrophoretic mobility
as the wild type cytochrome, indicating expression of the full-size
recombinant protein, was seen for each of the mutants except H54Q
and H122Q (data not shown); the latter two recombinant proteins
were, however, detected by themore sensitive dot blot assay (Table 1).
The data in Table 1 also show that the wild type cytochrome and the
negative control mutant (N78K) were expressed at high levels, fully
extractable with detergent, and almost entirely functional (i.e.,
reduced by ascorbate). The H92Q, H110Q and H109Y mutants were
also well expressed, and detergent-extractable in functional form. The
higher value for functional cytochrome than for recombinant protein
with the H110Q mutant probably reﬂects slightly different responses
for the immunological and spectroscopic assays. Recombinant protein
expression was much lower (and a lower fraction was extractable) for
the mutants at His 54, 88, 122 and 161 (Table 1), indicating that these
four histidine residues are important for efﬁcient expression of cyt
b561. Almost identical, and very low, levels of expression were found
for mutants at His 54 and 122, suggesting that these two residues
function as a pair, consistent with their roles as axial ligands to one of
the hemes (Fig. 2) [15]. Almost identical and somewhat higher levels
of expressionwere found for themutants at His 88 and 161, suggesting
that these two residues function as a second pair, consistent with their
identiﬁcation as axial ligands for the second heme (Fig. 2) [15].
3.2. Effects of His92 and His110 mutations on heme content, absorbance
spectra and ascorbate reactivity
Each recombinant protein, except the mutants at His54 and
His122, was puriﬁed by metal ion afﬁnity chromatography followed
by size exclusion chromatography before characterization of their
heme content, absorbance spectra and ascorbate reactivity. The heme
contents of wild type cyt b561 and the negative control N78K mutant
were 1.94 and 1.91 heme/monomer, respectively (Table 2). This is in
good agreement with values obtained for the endogenous cytochrome
puriﬁed from CG [12] and for the recombinant cytochrome expressed
in insect and yeast cell systems [13]. The heme content of the gluta-
mine and tyrosine mutants at His92 averaged 1.88 heme/monomer
and that of the glutamine and tyrosine mutants at His110 averaged
1.92 heme/monomer (Table 2). The tyrosine substitution at His109 had
1.87 heme/monomer. Each of these recombinant proteins thus carried
a full complement of the prosthetic group.
The absorbance spectrum of recombinant wild type cyt b561 is
shown in Fig. 3A. The ferric cytochrome has a prominent Soret peak at
415 nm with an absorbance coefﬁcient of 122 (mM heme)−1 cm−1
(Table 2). Note that heme was used as the basis for the absorbance
coefﬁcients to facilitate comparison among mutants with differing
heme stoichiometries (see below). Reduction with ascorbate shifted
the Soret peak to 427 nm and produced alpha and beta bands at 561
and 530 nm. Further addition of dithionite increased the intensity of
the Soret band by only a few percent, conﬁrming full reduction by
ascorbate. In this initial screening, recombinant cyt b561 with muta-
tions at His92, His110, or His109 displayed optical properties similar to
those of the wild type cytochrome (Table 2 and Fig. 3B). Each of these
mutants was essentially completely reduced by addition of 17–20 mM
ascorbate. The retention of grossly native optical properties and
functional interaction with ascorbate conﬁrm that His92, His110, and
His109 do not furnish axial ligands to either of the hemes in cyt b561.
The oxidized and reduced absorbance spectra for N78K, the negative
control, were essentially the same as those of the wild type cyto-
chrome (data not shown).
The heme content for two mutants at His88 and two mutants at
His161 ranged from 0.9 to 1.6 heme/monomer (Table 2). This indicates
a loss of some heme from one or both sites. In the oxidized state, each
of the solubilized and partially puriﬁed mutants at His88 or His161had a prominent Soret peak (spectra for H161Q are shown as
examples in Fig. 3C), but the peak was shifted to shorter wavelengths
than with the wild type (Table 2). This blue-shift could reﬂect hetero-
geneity in the low-spin species as well as a low-spin to high-spin
conversion for a portion of the heme. In this connection, the EPR
spectra of the His88 and His161 mutants exhibited prominent high-
spin signals near g=6 (data not shown). Although not quantitated
rigorously, comparison of the EPR spectra with those of high-spin and
low-spin myoglobin derivatives suggest that the amount of high-spin
heme in the His88 and His161 mutants is substantial, conceivably
representing one-half of the endogenous heme. However, as both the
g=3.7 and g=3.1 signals are modiﬁed in these mutant proteins (see
below and Fig. 4B) the high-spin heme signal could arise from either
heme center or a mixture of both.
None of the mutants at His88 or His161 was reduced signiﬁcantly
by ascorbate. Each of the His88 and His161 mutants was reduced by
dithionite, but the absorption coefﬁcients of the Soret and alpha bands
were considerably less than those of the wild type (Table 2). The alpha
band reveals the presence of low-spin species, while the decrease in
absorption coefﬁcient and the increased width of the Soret band
suggest that these mutants comprise a mixture of low-spin species
with different positions of the absorbance maximum, although the
presence of some high-spin species is apparent in the EPR spectra.
The optical background in host cell membrane extract put through the
same puriﬁcation steps was negligible (Fig. 3D), conﬁrming that the
absorbance spectra of the His88 and His161 mutants originate from
the heme in the recombinant cytochromes and not from any co-
purifying endogenous bacterial proteins.
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of cyt b561
The EPR spectrum of wild type cyt b561 puriﬁed from bacterial cells
(Fig. 4A) shows prominent low-spin ferric heme signals at g=3.71
from the low-potential center (bL) and at g=3.15 from the high-
potential heme center (bH) [13–16,33]. The high-spin ferric heme
signal at g=6 and that of “adventitious” ferric iron at g=4.3 are quite
small (data not shown). Mutation of His92 perturbed the high-
potential (bH) signal, with a shift to g=3.12 in H92Y and a shift to
g=3.22 in H92Q (Fig. 4A). This indicates that the sidechain of residue
92 inﬂuences the geometry of the bH heme center. The proximity of
His92 to the heme coordinated by the His88/His161 pair in the amino
acid sequence and in the structural model (Fig. 2) suggests that this
heme is the bH center. In contrast, the EPR spectra of both His110
mutants and the N78K and H109Y mutants are similar to that of the
wild type (Fig. 4A). An important point here is that the retention of
EPR signals for the bH and bL heme centers in all mutants at His92,
His109, and His110 is an additional reason to rule out these histidines
as axial ligands to the cyt b561 hemes.
EPR spectra were also recorded for partially puriﬁed recombinant
cyt b561 mutants at His88 or His161 (Fig. 4B). In each of the four
mutants, both the bH signal at g=3.15 and the bL signal at g=3.71
disappeared and were replaced by a broad, diffuse signal centered at
g=3.6 that is unlikely to represent a single species, and a signal at
g=2.97 that is probably a relaxed form of bis-histidine heme [15]. A
control membrane extract subjected to the same puriﬁcation
procedure as the mutant extracts had negligible EPR signals in the
range examined, demonstrating that these EPR signals originated
from the recombinant cytochrome and not from endogenous bacterial
host protein. These results support the assignment of His88 and
His161 as axial ligands to one of the heme centers [15,19,22,34] and
further indicate that there is a structural linkage between the twoFig. 5. Ascorbate titrations of recombinant cyt b561. Optical spectrawere recorded during indiv
heme) and H110Q (C; 9.4 µM heme) mutants. The fractional increases in A561 are plotted as a f
(open triangles) and H110Q (ﬁlled triangles). The lines are the non-linear regression ﬁts toheme centers so that disruption of either axial ligand at the His88/
His161 bH heme center perturbs the bL heme center as well [15].
3.4. Effects of mutations of His92 and His110 mutations on cyt b561
reduction by ascorbate
The reaction of ascorbate with cyt b561 mutants at His92, His110
and His109 was examined in more detail by following the increases in
alpha band intensity during titrations with ascorbate (examples are
shown in Fig. 5A–C). In each case, the increase in A561, expressed as a
fraction of the overall absorbance increase at the end of the titration,
appeared to go through two transitions (Fig. 5D). The ﬁrst transition
occurs at a low ascorbate level, reﬂecting reduction of the high-
potential (bH) heme center; this midpoint ascorbate concentration is
denoted as CH. The second transition occurs at higher ascorbate levels,
reﬂecting reduction of the low-potential (bL) heme center; this
midpoint ascorbate concentration is denoted CL. Fitting each titration
as the sum of two hyperbolae yields estimates of the two apparent
equilibrium constants (CH and CL), each of them a yet-to-be resolved
composite of the redox and ascorbate binding properties of the two
heme centers, and the fraction of the overall absorbance change
associated with the high-potential transition (FH) and that associated
with the low-potential transition (1−FH) (Table 3). The wild type
cytochrome had average CH and CL values of 5.4 and 369 µM ascorbate,
respectively, with 59% of the overall ΔA561 associated with the ﬁrst
transition.
Ascorbate solutions can decompose in air if trace metals are
present [35], so parallel ascorbate titrations of wild type cytochrome
were carried out under anaerobic conditions for comparison. The
resulting average parameter values from the anaerobic titrations were
statistically indistinguishable from those for the aerobic titrations
(Table 3), conﬁrming that ascorbate decomposition was not a sig-
niﬁcant problem under the conditions used for the present titrations.idual ascorbate titrations of wild type cyt b561 (A; 7.8 µM heme) and the H92Q (B; 7.8 µM
unction of the ascorbate concentration in panel D for wild type (WT; ﬁlled circles), H92Q
the equation given in Table 3.
Table 3
Ascorbate titration parameters for wild type and mutant cyt b561 proteins
Cyt b561a FHb CHb (μM) CLb (μM)
Wild type (n=7) 0.59±0.03 5.4±1.5 369±119
Wild type (n=3) (anaerobic) 0.62±0.02 5.2±0.4 318±50
N78K (n=2) 0.56±0.04 5.2±1.9 380±190
H92Q (n=2) 0.59±0.05 10.3±3.7c 270±70
H92Y (n=2) 0.49±0.02c 11.6±1.7c 1340±170c
H109Y (n=2) 0.64±0.03 5.0±0.1 460±60
H110Q (n=2) 0.70±0.03c 7.0±2.8 250±50
H110Y (n=4) 0.74±0.04c 7.5±1.3c 620±90c
a The number of titrations is given in parentheses. All titrations were performed
aerobically except where indicated.
b The normalized A561 increases (F) as a function of the ascorbate concentration
([Asc]) for each titration were ﬁtted to the equation: F=FH/(1+CH/[Asc])+(1−FH)/ (1+
CL / [Asc]), where FH and (1−FH) are the fractions of overall absorbance change
associated with the high- and low-potential hemes, respectively, and CH and CL are
the midpoints ascorbate levels for the high- and low-potential hemes, respectively. The
values shown represent the mean±standard deviation.
c pb0.05 by Student's t test (compared to aerobic wild type value).
Fig. 6. Alpha band difference spectra of high-potential (A) and low-potential (B) heme
centers of wild type and mutant cyt b561 proteins obtained from ascorbate titrations.
Each spectrum for the high-potential heme was obtained by averaging the differences
in three pairs of spectra from early points in the titrations (e.g., for wild type: Fig. 5A #5–
#1, #6–#2, #7–#3). Each spectrum for the low-potential heme was obtained by
averaging the differences in three pairs of spectra from later points in the titrations (e.g.,
for wild type: Fig. 5A #15–#10, #14–#9, #13–#8).
Table 4
Effects of mutations on widths of bH and bL alpha bands and the positions of their
resolved components
Cyt b561
mutant
Width at 75%
height (nm)a
Shift in peak position, relative to wild typeb
(nm)
bH bL bH-1 bH-2 bL-1 bL-2
Wild type 8.3 7.1 0 0 0 0
N78K 8.6 7.0 −0.2 +0.0 −0.1 +0.4
H92Q 6.1 7.0 +1.7 +0.8 +0.3 +0.4
H92Y 7.6 6.6 +0.7 +1.7 +0.0 +0.0
H109Y 8.8 7.1 −0.1 +0.1 −0.2 +0.0
H110Q 8.8 8.2 +0.1 +0.1 +0.3 +0.6
H110Y 8.4 7.5 +0.6 +0.9 +1.0 +1.0
a From spectra in Fig. 6.
b The positions of the major resolved bands in wild type cyt b561 were: bH-1,
561.0 nm; bH-2, 554.6 nm; bL-1, 560.8; bL-2, 555.3 nm. Shifts were rounded to the
nearest integer.
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protocol has given consistent results for several operators working on
many batches of wild type cytochrome over the course of more than
two years. The ascorbate titration thus seems to be a reliable,
quantitative and convenient method to assess the functionality of
the two hemes in cyt b561.
The negative control mutant, N78K, had ascorbate titration
parameters essentially the same as the wild type (Table 3). Substitu-
tion with glutamine or tyrosine at His92 led to more than doubling of
the CH value, but only the tyrosine substitution perturbed the CL value
signiﬁcantly; neither mutation signiﬁcantly affected the relative
proportions of the two transitions. Substitution with glutamine or
tyrosine at His110 signiﬁcantly decreased the absorbance change
associated with the bL transition, seen as an increase in the value of FH
(Table 3). The alterations in CH and CL values seen with the H110Y
mutant may be consequences of the decreased contribution of the bL
absorbance change. The titration parameters of the H109Y mutant
were indistinguishable from the wild type, suggesting that His109
does not contribute to ascorbate interactions or to the redox behavior
at either heme center. Overall, the N78K and H109Y mutations had
little effect on the ascorbate titration parameters, whereas both
mutations at His92 affected the ascorbate midpoint for the bH
transition and both the His110 mutations affected the magnitude of
the bL absorbance change. Tyrosine substitutions at either His92 or
His110 affected both the bH and bL transitions, suggesting that these
particular substitutions at one heme center affected the behavior of
the other heme center.
3.5. Effects of His92 and His110 mutations on visible absorbance bands
The ascorbate concentrations needed to reduce the high- and low-
potential heme centers differ signiﬁcantly for wild type and mutant
cytochromes (Table 3). Accordingly, the differences between succes-
sive spectra at the beginning of the present titrations were used to
obtain the spectra of bH and the differences between successive
spectra toward the end of the titrations were used to obtain the
spectra of bL. The resulting spectra for the wild type cytochrome and
six mutants, normalized to the same alpha band intensity, are shown
in Fig. 6. For the bH spectra (Fig. 6A), only the H92Q and H92Ymutants
are shifted and have a different shape from the wild type cytochrome.
This difference in shape is also evident in the peakwidth values, which
are narrower than those of other mutants (Table 4). The differences
among the bL spectra (Fig. 6B) were more subtle but changes in shape
were evident in thewidth of the alpha band (Table 4). The peakwidths
for the H110Q and H110Y mutants were notably wider than those of
the wild type and the other mutants. Clearly, substitutions at His92had a selective effect on the alpha band characteristics of bH, whereas
substitutions at His110 selectively affected the bL alpha band.
The alpha band components of bH and bL for wild type cyt b561 and
each of the mutants obtained from ascorbate titration spectra as
described above were further analyzed by resolution into three
Gaussian components, two from transitions in the alpha band itself
and one extending from a transition of the beta band, as shown for the
recombinant wild type cytochrome in Fig. 7. The positions of the two
main maxima in these resolved spectra, relative to the wild type
maxima near 561 and 555 nm, are shown in Table 4. Bothmutations of
His110 led to shifts in the two major bL alpha band components, with
smaller affects on the major bH components. In contrast, both
mutations of His92 showed shifts in the positions of the two major
Table 5
Redox parameters of wild type and mutant cyt b561
FH
a Em(bL) (mV)a Em(bH) (mV)a
Wild type (n=3)b 0.45±0.01 60±4 151±17
N78K (n=3) 0.49±0.02c 87±6c 174±10
H92Q (n=3) 0.54±0.08 72±13 162±16
H92Y (n=5) 0.39±0.04 13±12c 157±20
H109Y (n=3) 0.45±0.04 84±6c 176±15
H110Q (n=6) 0.48±0.05 77±7c 171±19
H110Y (n=3) 0.45±0.01 76±1c 165±7
a Values of the fraction of maximal change in A561 were analyzed as a function of the
redox potential as described in Section 2. FH and (1−FH) are the fractions of the maximal
absorbance change associated with the high- and low-potential hemes, respectively; Em
(bL) and Em(bH) are the midpoint potentials for the low- and high-potential hemes,
respectively. The values shown represent the mean±standard deviation.
b Number of reductive or oxidative titrations analyzed.
c pb0.05 by Student's t test (compared to wild type value).
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the bL-2 component similar to that seen with the N78K control. The
H109Y mutant did not affect the position of any of the resolved
spectral components, and the N78K mutant led to a small shift in only
one component of bL. As for the comparison of the overall alpha band
characteristics described above, the results of the resolution show that
substitutions at His92 had a selective effect on the alpha band
characteristics of bH, whereas substitutions at His110 selectively
affected the bL alpha band.
Overall, three separate aspects of the ascorbate titration data were
analyzed: the concentrations of ascorbate required for the bH and bL
redox transitions, the bH and bL alpha band characteristics as a whole,
and the characteristics of the bH and bL alpha band components. The
consistent, general pattern observed was that substitutions at His92
affected the bH heme center, substitutions at His110 affected the bL
heme center, and substitutions at His109 had only modest effects on
either heme center. This pattern indicates that His92 is in the vicinity
of the bH heme center and His110 is near the bL heme center. His92 is
just four residues away from one of the axial ligands, His88, with the
two residues on the same face of an alpha-helix; His92 is positioned
close to His88 in the 3D model shown in Fig. 2. Optical spectral
changes during the functional reactionwith ascorbate thus link the bH
center to His88 and its partner, His161, and the bL center to the His54/
His122 ligand pair. Supporting the latter assignment is the close
proximity of His110 to His54 in the 3D model (Fig. 2) and in models of
the arrangement of the transmembrane helices [19].
3.6. Effects of His92 and His110 mutations on heme redox potentials
Potentiometric titrations monitoring alpha band absorbance
changes were used to examine the effects of mutations on the ferric/
ferrous heme couples in recombinant cyt b561 (Table 5). Wild type
cyt b561 had average midpoint potentials at 60 and 151 mV, with
approximately half of the A561 change in each transition. These redox
potentials fall in the ranges of 30–70mV and 145–170mV reported for
the cytochrome from CG [17,18,33]. None of the cyt b561mutants had a
large difference with thewild type cytochrome in terms of the relative
proportions contributed by the two heme centers. All but one of theFig. 7. Alpha band difference spectra during ascorbate titration of wild type (WT) cyt
b561 (panel A) and resolution of alpha band components of low-potential heme (bL,
panel B) and high-potential heme (bH, panel C). The resolution of alpha band spectra
(from Fig. 6) into three Gaussian components was accomplished with Origin 6.1
software using a Levenberg–Marquardt non-linear regression algorithm. The only
constraint on the ﬁtting was that the position of the maximum of the third Gaussian
component remained below 552 nm.cyt b561 mutants had midpoint potentials for the two heme centers
within 27 mV of the wild type values. The exceptionwas H92Y, where
the Em(bL) value was decreased to 13 mV. Still, none of the mutations
appears to have a dramatic effect on the redox properties of the heme
centers in cyt b561.
Comparison of the potentiometric titration results in Table 5 with
those from the ascorbate titrations in Table 3 reveals that when the
ratios of CL to CH are converted tomillivolts, the values are comparable
to the differences in redox potentials of the two hemes. This linkage
between CL/CH and ΔEm indicates that the redox reactions with
ascorbate approach a thermodynamic equilibrium. CH and CL thus
reﬂect a combination of heme redox and ascorbate binding properties
and are not simply afﬁnity or kinetic constants for ascorbate binding
as suggested by Berczi et al. [21]. The lack of major changes in redox
potentials in the mutations of His92 and His110 that domarkedly alter
CH and CL (Tables 3 and 5) suggests that these mutations impact
ascorbate binding and reactivity more than the intrinsic redox char-
acteristics of the hemes.
4. Discussion
4.1. Heme content and protein structure in His92 and His110 mutants
Substitutions of His92 and His110 with glutamine or tyrosine
produced distinct effects on the spectroscopic properties and the
functioning of adrenal cyt b561. These effects are useful in examining
the roles of His92 and His110 themselves, and also for characterizing
the individual heme centers, where mutations in the axial ligands
have proven generally disruptive for both heme centers and for the
protein overall (Tables 1 and 2, Figs. 3 and 4, Refs. [15,21]). All mutants
tested at His92 or His110 contained two molecules of heme, both of
which retained functional reaction with ascorbate (Table 2 and Fig. 3).
Murine cyt b561 was reported to retain reactivity with ascorbate when
the residue corresponding to His110was replaced with an alanine; the
residue corresponding to His92 was not tested [21].
4.2. His92 and His110 and characteristics of the heme centers
The bH and bL heme centers of cyt b561 can be distinguished by their
characteristic signals in EPR and optical spectra [12,14–16]. The EPR
spectra of the mutants at His92 and His110 were quite informative,
with the low-spin signal of the bH center (g~3.1) shifted in both H92Q
and H92Y, but unchanged in both H110Q and H110Y (Fig. 4), un-
ambiguously connecting His92 to the bH heme center. The low-spin bL
EPR signal at g~3.7was not affected bymutations at His92 or at His110.
The optical absorption spectra of the His92 and His110 mutants also
proved informative. The alpha bands for the two heme centers re-
solved from the ascorbate titration spectra (Fig. 6 and Table 4) revealed
that the bH alpha band was narrower in H92Q and H92Y but not in
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mutants but not in the His92 mutants. Overall, these results make it
clear that the sidechains of His92 and His110 can indeed affect the
properties of the heme centers, supporting the structural model of
Bashtovyy et al. (Fig. 2) [23]. Given the differing conservation of His92
and His110 between the four cyt b561 family subgroups in Fig. 1, we
speculate that the structures of residues 92 and 110 have evolved for a
specialized function peculiar to each group. Several other hemopro-
teins are known to have a histidine residue that is not an axial ligand
located near a heme residue. These include cytochrome c554 [36], cyt c3
[37], and yeast cyt c peroxidase [38]. The functional impact of the
“shadow” histidine residue has not been evaluated so far for any of
these proteins.
4.3. His92 and His110 and reaction of heme centers with ascorbate
Ascorbic acid is the physiological reductant for the adrenal
cytochrome [9] and the titrations with ascorbate provide a useful
probe of functional changes in the mutants (Fig. 5 and Table 3). The
exact nature of the constants CL and CH extracted from the titration of
cyt b561 with ascorbate remains to be clariﬁed. They appear to be
pseudo-equilibrium constants that are determined by a combination
of the hemes' redox properties and the afﬁnity of ascorbate for each of
its two binding centers. Berczi et al. [21] recently analyzed the
dependence of the reduction of murine cyt b561 and its mutants on
ascorbate concentration. They interpreted the parameters extracted
by ﬁtting as apparent afﬁnity constants for ascorbate. However,
additional experiments are needed to establish the exact contribu-
tions of ascorbate binding and heme redox properties to the values of
empirical constants such as CL and CH.
4.4. Topology of cyt b561 heme centers in chromafﬁn granules
The observed pattern of changes in the EPR and optical spectra and
in the ascorbate titrations for the His92 and His110 mutants described
above connects His92 to bH and His110 to bL. These assignments are
important because they have implications for the topology of the two
cyt b561 heme centers in the chromafﬁn granule membrane. The
topology of the adrenal cyt b561 polypeptide has not been directly
characterized, but the currently accepted model from sequence
analysis has six transmembrane helices, with the N- and C-termini
exposed on the cytoplasmic (C) side of the CG membrane [39]. The C-
terminus is known to be accessible to proteases from the C-side of
intact CG vesicles [40]. This topology positions His54 and His122
towards the matrix (M) side, and His88 and His161 toward the C-side,
of the CG membrane. The primary structure puts His92 near His88, so
the bH heme is that coordinated by His88 and His161, on the C-side of
the CGmembrane. By elimination, the bL hememust be coordinated by
His54 and His122, on the M-side of the membrane. Further evidence
for the assignment of bL to the His54/His122 heme is the observation
that murine adrenal cyt b561with alanine substitutions of the residues
corresponding to His88 and His161 retained only the heme center (bL)
that is less reactive with ascorbate in equilibrium titrations [21]. The
disposition of the two heme centers relative to the membrane
indicated by these results is the opposite of that assumed in some
current models [41], but it is consistent with conclusions drawn from
the observation of some g=3.7 EPR signal (from the bL center) in H88Q
and H161Q mutants of cyt b561 expressed in Sf9 cells [15].
4.5. Effects of mutations at Asn78 and His109
Residue 109 (a histidine in bovine cyt b561 and a tyrosine in the
human cytochrome) is positioned on the periphery of the four-helix
bundle in the computational model (Fig. 2). Thus, it was not surprising
that substitutions of His109 had little effect on expression of the
cytochrome or on the spectroscopic and functional properties (Figs. 4and 6; Tables 1, 2, 3 and 4). Asn78 was selected as a negative control
target for mutagenesis because it is predicted to lie on the periphery of
the four-helix bundle (Fig. 2). Surprisingly, the N78K mutation was
found to increase expression of the recombinant cytochrome (Table 1),
which may make this protein useful for structural studies. Asn78 is
predicted to be in the cytoplasmic loop connecting helices 2 and 3 and
may well have important structural interactions with cytoplasmically-
exposed residues in the N- or C-terminal segments or the loop
connecting helices 4 and 5. The N-terminal segment preceding helix 1
is positioned next to the loop between helices 2 and 3 in one variant of
the computational model [23].
4.6. Functional integration of the two heme centers
The effects of point mutations at His88 and His161 (Fig. 3) show
that just a single mutation at either histidine is sufﬁcient to prevent
reduction of all heme in the cytochrome by ascorbate. The proportion
of ascorbate-reducible cytochrome was also greatly diminished in
murine cyt b561 mutants with alanine substitutions at the residues
corresponding to His88 or His161 in the bovine cytochrome, with only
5% of the wild type response to ascorbate retained in the double
mutant [21]. Overall, it is clear that the axial ligands to heme
contributed by His88 and His161 are crucial for physiological
reduction of the adrenal cyt b561 and that both heme centers are
impacted by the loss of structural integrity of the bH heme. We take
this coordinated behavior to reﬂect the integration of the two hemes
as part of a structural unit that we have termed the “kernel” [15].
Additional evidence for integration of the two heme centers comes
from the observation that the point mutants H92Yand H110Yaffected
some properties of both heme centers (Tables 3 and 4).
4.7. Heme centers and cyt b561 expression
Only a fraction of recombinant cyt b561 proteinwith substitutions in
His88 or His161 could be extracted by nonionic detergent (Table 1),
indicating thatmost of thesemutant proteinswere not properly folded
and/or integrated intomembrane. Similar low-detergent extractability
was observed when these mutants were expressed in Sf9 insect cells
[15]. Any substitutions in any one of the histidines furnishing axial
ligands to either of the cyt b561 hemes decreases expression of the
bovine (Fig. 3 and Table 1) [15], murine [21] and thale cress [42]
cytochromes,with comparable results in bacterial, yeast and insect cell
systems. The integrity of the ligation of both hemes is thus linked to
expression of functional cytochrome. Adrenal cyt b561 is an integral
membrane protein and carries an uncleaved signal peptide for
targeting the nascent polypeptide to the translocon machinery in the
endoplasmic reticulum membrane [27]. In the translocon-mediated
process, most polytopic proteins are integrated into the ER membrane
co-translationally [43], and interactions between adjacent transmem-
brane segments are known to promote stablemembrane integration of
these segments [44]. Incorporation of heme by a myeloperoxidase
precursor is a key step in that protein's maturation in the ER lumen
[45], and nascent globin polypeptides can bind heme [46]. A pair of
hemes with bis-histidine axial ligation has been found or proposed for
a number of membrane bound cytochromes, involving ligands on
either two [47–52], three [53], or four [54,55] transmembrane helices.
In some cases, mutation in the histidines furnishing axial ligands to
the hemes leads to decreased levels of functional protein, suggesting
a role for properly coordinated heme in protein synthesis or stability
[55,56].
A striking observation, found with both bacterial and yeast expres-
sion systems, is that mutations in the His54/His122 pair decrease ex-
pression of recombinant cyt b561 much more than substitutions in the
His88/His161 pair (Table 1) [21]. As ribosomal translation of the His54/
His122 pair is completed before that of the His88/His161 pair, the
differential effects on expression of mutations in the two pairs suggest
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assembly of the transmembrane cytochrome.
There is some precedent for diheme ligation being required for
proper expression of adrenal cyt b561, in that cofactor binding can
accelerate protein folding [57]. Direct examples for comparison with
cyt b561 are not plentiful. Other examples of diheme b cytochromes
with a 4-helix structural unit are found as subunits of hetero-
oligomeric complexes, making it difﬁcult to examine the expression of
these b cytochromes in isolation [54,55]. Cyt b562 from E. coli is a
monomeric 4-helix bundle protein with a single b-type heme, and
its folding behavior suggests that heme binds only after folding of the
4-helix bundle [58]. This bacterial cyt b562, however, is a globular
protein and the constraints of folding in an aqueous environment are
likely very different from those encountered by the adrenal cyto-
chrome during membrane insertion. The small size, convenient ex-
pression, and sensitive spectroscopic characteristics of cyt b561make it
an attractive experimental model for more detailed characterization
of cofactor inﬂuences on membrane protein biogenesis.
In summary, the present results indicate that the sidechains of
His92 and His110 in adrenal cyt b561, although not axial ligands to
either heme, nonetheless selectively inﬂuence the cytochrome's
spectroscopic properties and its interactions with ascorbate, support-
ing the identiﬁcation of His92 and His110 as components of the bH and
bL heme domains, respectively.
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